New results of combination endocrinotherapy with ribocyclib


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analysis of the results of studies on the efficacy of ribocyclib as the first-line treatment in pre- and perimenopausal patients with HR+ HER2-advanced breast cancer (BC) was carried out. It was concluded that the combination therapy with ribocyclic and aromatase inhibitors is highly effective for pre- and perimenopausal BC patients against the background of ovarian suppression. Available data allow to conclude that this combination helps not only to delay the onset of further progression, but also to increase the life expectancy of patients while maintaining its quality, regardless of the location of metastases.

Full Text

Restricted Access

About the authors

I. V Kolyadina

Russian Medical Academy of Continuous Professional Education

Email: irinakolyadina@yandex.ru
MD, Prof, at the Department of Oncology and Palliative Medicine Moscow, Russia

References

  1. GLOBOCAN 2018; IACR, WHO, 2018. URL: http://gco.iarc.fr/today
  2. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г В. Петровой. М., 2018
  3. Yersa O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-24. doi: 10.5306/wjco.v5.i3.412.
  4. Практические рекомендации RUSSCO по лекарственному лечению инвазивного рака молочной железы. [RUSSCO practical guidelines for the treatment of invasive breast cancer. (In Russ.)]. URL: https://rosoncoweb.ru/standarts/ RUSSCO/2018/2018-08.pdf
  5. Jacquet E, Lardy-Cleaud A., Pistilli B., et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients. Eur J Cancer 2018;95:93-101. Doi: 10.1016/j. ejca.2018.03.013.
  6. Cronin K.A., Berry D.A. Concern Regarding Age Distribution of Breast Cancer. JAMA Surg. 2018;153(11):1060-61. Doi: 10.1001/ jamasurg.2018.2087.
  7. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758-67. doi: 10.1200/JCO.2000.18.22.3758.
  8. Mouridsen H., Gershanovich M., Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101-109. Doi: https://doi. org/10.1200/JCO.2003.04.194.
  9. Carlson R.W., Theriault R., Schurman C.M., et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010;28(25):3917-21. doi: 10.1200/JCO.2009.24.9565.
  10. Cheung K.L., Agrawal A., Folkerd E., et al. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer. 2010;46:2936-42. doi: 10.1016/j.ejca.2010.08.005.
  11. Park I.H., Ro J., Lee K.S., et al. Phase ii parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol. 2010;28:2705-11. Doi: 10.1200/ JCO.2009.26.5884.
  12. Kim N.K., lee S.H., Kim Y.J., et al. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. BMC Cancer. 2019;19(1):84. doi: 10.1186/s12885-018-5258-9.
  13. Hirama T., Koeffler H.P Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer. Blood. 1995;86:841-54.
  14. Fry D.W., Harvey P.J., Keller FIR., et al. Specific Inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427-37.
  15. Finn R.S., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. Doi: 10.1186/ bcr2419.
  16. Ганьшина И.П., Филоненко Д.А., Гордеева О.О. и др. Рибоциклиб в лечении гормонопозитивного HER2-негативного рака молочной железы. Медицинский совет. 2019;10:72-80.
  17. Жукова Л.Г., Ганьшина И.П., Гордеева О.О., Лубенникова Е.В. Рибоциклиб в 1-й линии терапии гормоночувствительного рака молочной железы. Современная онкология. 2018;20(2):38-41
  18. Tripathy D., Im S.A., Colleoni M., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptorpositive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-15. doi: 10.1016/S1470-2045(18)30292-4.
  19. Yardley D.A, et al. Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: subgroup analysis of phase III MONALEESA trials. Paper presented at: San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, TX. Abstract 1000.
  20. Bardia A, et al. Tamoxifen or a nonsteroidal aromatase inhibitor with ribociclib inpremenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 subgroup analysis. Poster presented at: European Society for Medical Oncology Congress; October 19-23, 2018; Munich, Germany. Poster 330P
  21. Im S., Lu Y, Bardia A., et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381:307-16. Doi: 10.1056/ NEJMoa1903765.
  22. Yardley D.A. MONALEESA clinical program: a review of ribociclib use in different clinical settings. Future Oncol. 2019;15(23):2673-86. doi: 10.2217/fon-2019-0130.
  23. Carlson R. The history and mechanism of action of fulvestrant. Clin Breast Cancer. 2005;6 Suppl 1:S5-8.
  24. Robertson J.F., Lindemann J.P, Llombart-Cussac A., et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST' study Breast Cancer Res Treat. 2012;136(2):503-11. doi: 10.1007/s10549-012-2192-4.
  25. Robertson J.FR., Bondarenko I.M., Trishkina E., et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005. Doi: 10.1016/ S0140-6736(16)32389-3.
  26. Slamon D.J., Neven P, Chia S., et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-72. Doi: 10.1200/ JCO.2018.78.9909.
  27. URL: https://oncologypro.esmo.org/media/ videos/ESMO-Channel/ESMO-2019-Highlights-in-HR-HER2-advanced-breast-cancer-The-MONALEESA-3-study
  28. Beck J.T., et al. Patient-reported outcomes with ribociclib-based therapy in hormone receptorpositive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, -7 trials. Paper presented at: San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, TX. 6.
  29. Beck J.T., et al. Ribociclib treatment benefit in patients with advanced breast cancer with 1 dose reduction: data from the MONALEESA-2, -3, and -7 trials. Paper presented at: San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, TX.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies